Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01372
|
|||||
| Drug Name |
Topiramate
|
|||||
| Synonyms |
Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Partial seizures [ICD11: 8A68.0] | Approved | [1] | |||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H21NO8S
|
|||||
| Canonical SMILES |
CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C
|
|||||
| InChI |
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
|
|||||
| InChIKey |
KJADKKWYZYXHBB-XBWDGYHZSA-N
|
|||||
| CAS Number |
CAS 97240-79-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 339.36 | Topological Polar Surface Area | 124 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
-0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9705
, 7847603
, 7980814
, 11039383
, 11484731
, 11488944
, 11528651
, 12013555
, 14777895
, 14924784
, 24724627
, 25819957
, 26612934
, 26719832
, 39317930
, 46386619
, 46508334
, 46511457
, 47277061
, 47425755
, 48416647
, 48764342
, 49681704
, 49835829
, 50070928
, 50123385
, 53787612
, 57359151
, 77351910
, 85248100
, 92124710
, 92307910
, 92308459
, 93167012
, 93167145
, 97857519
, 99437151
, 104109398
, 104234233
, 104971753
, 124658936
, 124757247
, 124800161
, 125164051
, 125312450
, 126525327
, 126606833
, 126670104
, 128389335
, 134337459
|
|||||
| ChEBI ID |
CHEBI:63631
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Topiramate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.